<DOC>
	<DOCNO>NCT02134977</DOCNO>
	<brief_summary>The purpose survey examine effect quality life ( QOL ) improvement convenience switch leuprorelin acetate 3 month depot 11.25 milligram ( mg ) injection kit ( Leuplin SR 11.25 mg injection kit ) 4-week adjuvant therapy luteinizing hormone-releasing hormone analog ( LH-RHa ) 1 month depot 48 week premenopausal breast cancer participant daily medical practice . Influence condition estrogen receptor expression efficacy safety leuprorelin acetate SR 11.25 mg injection kit also evaluate .</brief_summary>
	<brief_title>Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey : `` QOL Survey Premenopausal Breast Cancer Patients ''</brief_title>
	<detailed_description>This survey design examine effect QOL improvement convenience switch leuprorelin acetate 3 month depot 11.25 mg injection kit ( Leuplin SR 11.25 mg injection kit ) 4-week adjuvant therapy LH-RHa 1 month depot 48 week premenopausal breast cancer participant daily medical practice , well evaluate influence condition estrogen receptor expression efficacy safety leuprorelin acetate SR 11.25 mg injection kit . For adult , leuprorelin acetate SR 11.25 mg injection kit ( Leuplin SR 11.25 mg Injection Kit ) usually administer subcutaneously every 12 week . Prior injection , plunger rod syringe push upward needle point upward , allow entire suspension fluid contain transferred powder . The powder fully suspend fluid ensure bubble generate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Premenopausal breast cancer participant meet follow criterion enrol surveillance : 1 . Participants receive 4 week treatment repository LHRHa preparation within 1 week prior administration Leuplin SR 11.25 mg Injection Kit . 2 . Participants receive Leuplin SR 11.25 mg Injection Kit adjuvant therapy . 3 . Participants performance status grade 0 1 . 4 . Participants answer question `` QOL check sheet ( I ) '' start ( Week 0 ) treatment Leuplin SR 11.25 mg Injection Kit . Participants meet follow criterion exclude surveillance : 1 . Participants history hypersensitivity ingredient ( ) Leuplin SR 11.25 mg Injection Kit synthetic derivative luteinizing hormonereleasing hormone ( LHRH ) LHRH . 2 . Pregnant woman , possibly pregnant woman , nurse mother . 3 . Participants advance ( T4 M1 accord TNM classification [ General Rules Clinical Pathological Recording Breast Cancer : 16th edition ] ) recurrent breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>